Kidney transplant trial using two diabetes medicines safely
Treatments studied
Part of Hormones & metabolism clinical trials.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have had a kidney transplant (KTR) for more than 3 months
- Your kidney function (eGFR) is at least 20
- Your blood pressure is between 90/60 and under 160/100 at screening
- Your body weight range (BMI) is 18.5 to 40
- If you have type 2 diabetes or post-transplant diabetes, your last HbA1c is under 12%
- You can sign consent and follow study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This trial tests a medicine called an SGLT2 inhibitor (which helps lower blood sugar) in people who have had a kidney transplant and do not have diabetes. The goal is to see if it can prevent new diabetes from developing after a transplant and help protect the transplanted kidney.
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
This trial tests whether the medication semaglutide (often used for diabetes) can prevent the development of new diabetes after a kidney transplant. If you are in the early weeks after a transplant and have risk factors for diabetes, this study might help reduce your chances of developing diabetes later.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
Hear when a new Kidney Transplant Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.